

(19)



(11)

EP 3 705 153 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):
A61M 25/00 (2006.01)

(52) Cooperative Patent Classification (CPC):
A61M 25/0014; A61M 25/0097

(48) Corrigendum issued on:
27.11.2024 Bulletin 2024/48

(45) Date of publication and mention
of the grant of the patent:
23.10.2024 Bulletin 2024/43

(21) Application number: **19161019.5**

(22) Date of filing: **06.03.2019**

(54) **INJECTION MOLDED CANNULA SYSTEM**

SPRITZGEGOSSENES KANÜLENSYSTEM

SYSTÈME DE CANULE MOULÉ PAR INJECTION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(72) Inventors:

- **FREITAG, Christian**
68305 Mannheim (DE)
- **RASMUSSEN, Mads**
68305 Mannheim (DE)

(43) Date of publication of application:
09.09.2020 Bulletin 2020/37

(74) Representative: **Rentsch Partner AG**
Kirchenweg 8
Postfach
8034 Zürich (CH)

(73) Proprietors:

- **Roche Diabetes Care GmbH**
68305 Mannheim (DE)
Designated Contracting States:
AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT
RO SE SI
- **F. Hoffmann-La Roche AG**
4070 Basel (CH)
Designated Contracting States:
AL CH CY CZ ES GB GR HR HU IE IS LI MC MK
NO PL RS SK SM TR

(56) References cited:
WO-A2-99/21605 DE-C1- 3 530 349
US-A- 4 430 081 US-A- 4 781 703

EP 3 705 153 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).